Viridian Therapeutics, Inc. (VRDN)
24.18
+0.16
(+0.67%)
USD |
NASDAQ |
Aug 25, 16:00
24.18
0.00 (0.00%)
After-Hours: 19:59
Viridian Therapeutics Enterprise Value : 2.079B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.079B |
| August 21, 2026 | 2.110B |
| August 20, 2026 | 2.134B |
| August 19, 2026 | 2.168B |
| August 18, 2026 | 2.069B |
| August 17, 2026 | 1.974B |
| August 14, 2026 | 1.860B |
| August 13, 2026 | 1.849B |
| August 12, 2026 | 1.950B |
| August 11, 2026 | 1.960B |
| August 10, 2026 | 1.971B |
| August 07, 2026 | 2.031B |
| August 06, 2026 | 1.908B |
| August 05, 2026 | 1.745B |
| August 04, 2026 | 1.719B |
| August 03, 2026 | 1.546B |
| July 31, 2026 | 1.502B |
| July 30, 2026 | 1.613B |
| July 29, 2026 | 1.611B |
| July 28, 2026 | 1.569B |
| July 27, 2026 | 1.590B |
| July 24, 2026 | 1.541B |
| July 23, 2026 | 1.540B |
| July 22, 2026 | 1.530B |
| July 21, 2026 | 1.531B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.461B |
| July 17, 2026 | 1.401B |
| July 16, 2026 | 1.401B |
| July 15, 2026 | 1.518B |
| July 14, 2026 | 1.520B |
| July 13, 2026 | 1.510B |
| July 10, 2026 | 1.595B |
| July 09, 2026 | 1.647B |
| July 08, 2026 | 1.608B |
| July 07, 2026 | 1.677B |
| July 06, 2026 | 1.510B |
| July 02, 2026 | 1.556B |
| July 01, 2026 | 1.452B |
| June 30, 2026 | 1.440B |
| June 29, 2026 | 1.346B |
| June 26, 2026 | 1.255B |
| June 25, 2026 | 1.203B |
| June 24, 2026 | 1.196B |
| June 23, 2026 | 1.192B |
| June 22, 2026 | 1.227B |
| June 18, 2026 | 1.125B |
| June 17, 2026 | 1.133B |
| June 16, 2026 | 1.058B |
| June 15, 2026 | 1.091B |
| June 12, 2026 | 1.096B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
| Savara, Inc. | 999.39M |
| Vericel Corp. | 2.097B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -127.12M |
| Revenue (Quarterly) | 0.284M |
| Total Expenses (Quarterly) | 127.40M |
| EPS Diluted (Quarterly) | -1.178 |
| Gross Profit Margin (Quarterly) | 58.80% |
| Profit Margin (Quarterly) | -44.76K% |
| Earnings Yield | -15.34% |
| Normalized Earnings Yield | -15.50 |